Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2024-11-25

Clinical Trial Update: A Study on Switching From Daily DPP-4 Inhibitor to HSK7653 in Type 2 Diabetes Patients [Phase 2]

View source ↗

Summary

This Phase 2 trial update reports results from switching Type 2 diabetes patients from a daily DPP-4 inhibitor to HSK7653.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • HSK7653

Snippet

Sponsor: Haisco Pharmaceutical Group Co., Ltd. | Conditions: Type 2 Diabetes | Phase 2 | Status: COMPLETED